Literature DB >> 31038300

N-Acetylcysteine augmentation in refractory obsessive–compulsive disorder

Sreenivasa Bhaskara1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31038300      PMCID： PMC6488488          DOI： 10.1503/jpn.180179

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  11 in total

1.  N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Authors:  Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric
Journal:  Psychopharmacology (Berl)       Date:  2005-12-22       Impact factor: 4.530

2.  Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.

Authors:  David S Baldwin; Ian M Anderson; David J Nutt; Borwin Bandelow; A Bond; Jonathan R T Davidson; J A den Boer; Naomi A Fineberg; Martin Knapp; J Scott; H-U Wittchen
Journal:  J Psychopharmacol       Date:  2005-11       Impact factor: 4.153

3.  N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.

Authors:  Jerome Sarris; Georgina Oliver; David A Camfield; Olivia M Dean; Nathan Dowling; Deidre J Smith; Jenifer Murphy; Ranjit Menon; Michael Berk; Scott Blair-West; Chee H Ng
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 4.  N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Authors:  Olivia Dean; Frank Giorlando; Michael Berk
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 5.  Treatment non-response in OCD: methodological issues and operational definitions.

Authors:  Stefano Pallanti; Eric Hollander; Carol Bienstock; Lorrin Koran; James Leckman; Donatella Marazziti; Michele Pato; Dan Stein; Joseph Zohar
Journal:  Int J Neuropsychopharmacol       Date:  2002-06       Impact factor: 5.176

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

7.  Glutamatergic agents for OCD and related disorders.

Authors:  Christopher Pittenger
Journal:  Curr Treat Options Psychiatry       Date:  2015-09

8.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

Authors:  Borwin Bandelow; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Borwin Bandelow; Christer Allgulander; José Ayuso-Gutierrez; David S Baldwin; Robertas Buenvicius; Giovanni Cassano; Naomi Fineberg; Loes Gabriels; Ian Hindmarch; Hisanobu Kaiya; Donald F Klein; Malcolm Lader; Yves Lecrubier; Jean-Pierre Lépine; Michael R Liebowitz; Juan José Lopez-Ibor; Donatella Marazziti; Euripedes C Miguel; Kang Seob Oh; Maurice Preter; Rainer Rupprecht; Mitsumoto Sato; Vladan Starcevic; Dan J Stein; Michael van Ameringen; Johann Vega
Journal:  World J Biol Psychiatry       Date:  2008       Impact factor: 4.132

Review 9.  The promise of N-acetylcysteine in neuropsychiatry.

Authors:  Michael Berk; Gin S Malhi; Laura J Gray; Olivia M Dean
Journal:  Trends Pharmacol Sci       Date:  2013-01-29       Impact factor: 14.819

10.  N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Hamid Afshar; Hamidreza Roohafza; Hamid Mohammad-Beigi; Mohammad Haghighi; Leila Jahangard; Pedram Shokouh; Masoumeh Sadeghi; Hasan Hafezian
Journal:  J Clin Psychopharmacol       Date:  2012-12       Impact factor: 3.153
View more
  1 in total

Review 1.  The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.

Authors:  Richard C J Bradlow; Michael Berk; Peter W Kalivas; Sudie E Back; Richard A Kanaan
Journal:  CNS Drugs       Date:  2022-03-22       Impact factor: 6.497
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.